PT  - JOURNAL ARTICLE
AU  - Dong-Yeon Kim
AU  - Ayoung Pyo
AU  - Misun Yun
AU  - Ramar Thangam
AU  - Sung-Hwan You
AU  - Ying Zhang
AU  - Ye-rim Jung
AU  - Dinh-Huy Nguyen
AU  - Akhil Venu
AU  - Hyeon Sik Kim
AU  - Mee Sun Yoon
AU  - Yeongjin Hong
AU  - Jung-Joon Min
TI  - Imaging Calreticulin for Early Detection of Immunogenic Cell Death During Anticancer Treatment
AID  - 10.2967/jnumed.120.245290
DP  - 2021 Jul 01
TA  - Journal of Nuclear Medicine
PG  - 956--960
VI  - 62
IP  - 7
4099  - http://jnm.snmjournals.org/content/62/7/956.short
4100  - http://jnm.snmjournals.org/content/62/7/956.full
SO  - J Nucl Med2021 Jul 01; 62
AB  - Surface-exposed calreticulin (ecto-CRT) is a well-known “eat-me” signal exhibited by dying cells that contributes to their recognition and destruction by the immune system. We assessed the use of a CRT-specific binding peptide for imaging ecto-CRT during immunogenic cell death and its utility for early prediction of treatment response. Methods: A synthetic CRT-specific peptide, KLGFFKR (CRTpep), was labeled with fluorescein isothiocyanate or 18F, and the characteristics of ecto-CRT were evaluated in a colon cancer cell line in vitro and in vivo. Results: In vitro flow cytometry, immunofluorescence staining, and in vivo small-animal PET imaging results showed that CRTpep detected preapoptotic cells treated with immunogenic drugs or radiation but not those treated with the nonimmunogenic drug or a nontherapeutic dose of immunogenic drug. Conclusion: The present results indicate that the CRT-specific peptide would enable the prediction of therapeutic response, thereby facilitating early decisions on continuation or discontinuation of immunogenic treatment.